samedan logo

 
 
spacer
home > ebr
PUBLICATIONS

European Biopharmaceutical Review

 

European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America, and the rest of the world.

With editorial consisting of in-depth articles, case studies, meetings, and report reviews written by specialists with hands-on experience in the biopharma industry; traditional multi-national pharma companies; investment houses; and industry-associated governmental, economic, and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focusses on geographic or therapeutic territories.

For further information please contact:

Advertising

Sam Bromley

 

Editorial

Vanessa Kintu

 

 

Connect with us on Twitter: follow @EBRmagazine

Read our publications on the go in the Samedan app for phones and tablets. You can download issues for offline reading, and our archives go as far back as 2008! Download for free on the App Store, GooglePlay, or Amazon.

     


Click here to view the digital version of EBR


 


ebr
 
 
Featured in this issue
DNA and RNA Sequencing
The Genetic Revolution

Is Genetic Anonymity Possible?

Dr Tal Sines and Ofer A Lidsky at DNAtix consider the hardly new, but still relevant, notion of a genetic revolution, and what this means in a modern context compared to when the term was first coined.
Features
Medicinal Cannabis

Why the Regulation of CBD Isnít ABC

Greer Deal at Global Regulatory Services maps the controversial history of cannabis, the fast-changing regulations for cannabisderived products, and the effect all the aforementioned may have on the market for cannabis-based drugs.
  Data Compliance and Misuse
Achieving Data Quality in Pharma Traceability Systems

The Elegant Fundamentals

Amit Sewak at rfxcel takes you through the fundamentals of ensuring the accuracy of pharmaceutical data; ranging from respecting the human element to effectively utilising the technology at your disposal.


spacer


Published quarterly in
January, April,
July, and October



 
Widgets Magazine

Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 
News and Press Releases

High Throughput Analytics Herald a Paradigm Shift in the Development of Biopharmaceuticals

Heilbronn/Dortmund August 2019: Biopharmaceuticals have revolutionized therapies of various diseases. In particular with regard to chronical and/or severe clinical conditions like multiple sclerosis, rheumatoid arthritis or cancer they are considered the future of treatment. Also economically biological drugs are on their way up: The global biopharmaceuticals market is anticipated to reach about 400 billion USD by 2025. Which strategic alignment will help best to fill a successful pipeline?
More info >>

 
White Papers

Running Better Trials Taking an Intelligent Monitoring Approach

Bioclinica

When it comes to implementing a risk-based monitoring program, it is not just about reducing monitoring visits and doing less Source Document Verification (SDV). Itís about bringing together your people, a solid process, and the right technology to run a better trial. Success with risk-based monitoring requires the ability to make sense of the thousands, if not millions, of data points captured by multiple disparate sources in a clinical trial. With the sheer volume of data generated on a daily basis comes complexity. How does one make sense of it all? Information overload burdens even the most experienced study teams who struggle to understand which data matters most and what it means.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement